Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Meril Life Sciences Pvt Ltd

    Incorporated in June 2007, Meril Life is engaged in the manufacturing of coronary stents and balloon catheters which are used for carrying out angioplasty on patients suffering

  • No Image
    Milan Laboratories India Pvt Ltd

    Milan Laboratories (India) Pvt. Ltd. was established in the year 1976 with the objective of manufacturing pharmaceutical formulations. The gradual expansion of the organisation

  • No Image
    Morepen Laboratories Ltd

    Morepen Laboratories Ltd is engaged in the manufacturing generic drugs and pharmaceutical formulations. The bulk drug manufacturing unit manufactures life saving drugs such as

  • No Image
    MSN Laboratories Ltd

    Founded in 2003, the Hyderabad based MSN Labs is one of the fastest growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple p

  • No Image
    Murli Krishna Pharma Pvt Ltd

    Murli Krishna Pharma Pvt Ltd was incorporated in 2004. The company was promoted by Late Mr. Eshwar Rao Vadlamani, Mrs. Satyaramani Vadlamani and Dr. Vijay Shastri. The company i